کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2101297 1546250 2016 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation
ترجمه فارسی عنوان
تأثیر بار سلول‌های پلاسمای مغز استخوان در بروز بقا در بیماران مبتلا به آمیلوئیدوز زنجیره سبک تحت پیوند ملفالان دوز بالا و سلول های بنیادی اتولوگ
کلمات کلیدی
سلول های پلاسما؛ زنجیره سبک (AL) آمیلوئیدوز؛ بقاء؛ ملپالان؛ پیوند سلول بنیادی
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی


• Overall survival of patients with light chain amyloidosis and bone marrow plasma cell burden  ≤ 10% and >10% did not differ after high-dose melphalan and stem cell transplantation
• Induction therapy for patients with bone marrow plasma cell burden > 10% and < 30% did not alter overall survival
• Hematologic complete response and relapse rates did not differ in patients with bone marrow plasma cell burden  ≤ 10% and >10% after high-dose melphalan and stem cell transplantation.

The prognosis in light chain (AL) amyloidosis has been linked to several variables, which are primarily related to end-organ damage. Recently, bone marrow plasma cell (BMPC) burden >10% has also been described as an adverse prognostic factor. We reviewed data pertaining to 546 patients with AL amyloidosis who underwent high-dose melphalan (HDM) and stem cell transplantation (SCT) to determine if BMPC > 10% was a negative prognostic factor. Of these patients, 445 had a BMPC burden ≤ 10% and 101 had a BMPC burden > 10%. Patients with BMPC > 30% were excluded from the study. The median overall survival (OS) was 7.86 years (95% confidence interval [CI], 6.69 to 9.83) in patients with BMPC ≤ 10% and 6.8 years (95% CI, 5.75 to 10.17) for those with BMPC >10% (hazard ratio, 1.106; 95% CI, .78 to 1.45; P = .70) after HDM/SCT. Of the 101 patients with a BMPC burden > 10%, 25 received induction therapy. The median OS was 7.78 years (95% CI, 5.4 to 13.4) for those without induction therapy and 5.75 years (95% CI, 3.94 to not available; P = .28) for those with induction therapy. Furthermore, hematologic response and relapse rates did not differ in these 2 groups after HDM/SCT. We conclude that BMPC > 10% and < 30% is not a poor prognostic factor with respect to survival in patients with AL amyloidosis treated with HDM/SCT and that induction therapy in this group does not impact OS.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: - Volume 22, Issue 9, September 2016, Pages 1729–1732
نویسندگان
, , , , ,